nodes	percent_of_prediction	percent_of_DWPC	metapath
Loperamide—CYP2B6—Sorafenib—thyroid cancer	0.0928	0.201	CbGbCtD
Loperamide—CYP2C8—Sorafenib—thyroid cancer	0.0703	0.152	CbGbCtD
Loperamide—CYP2B6—Doxorubicin—thyroid cancer	0.0563	0.122	CbGbCtD
Loperamide—ABCB1—Sorafenib—thyroid cancer	0.0476	0.103	CbGbCtD
Loperamide—CYP3A4—Vandetanib—thyroid cancer	0.0473	0.103	CbGbCtD
Loperamide—CYP2D6—Sorafenib—thyroid cancer	0.0448	0.0973	CbGbCtD
Loperamide—ABCB1—Doxorubicin—thyroid cancer	0.0289	0.0626	CbGbCtD
Loperamide—CYP3A4—Sorafenib—thyroid cancer	0.0285	0.0618	CbGbCtD
Loperamide—CYP2D6—Doxorubicin—thyroid cancer	0.0272	0.059	CbGbCtD
Loperamide—CYP3A4—Doxorubicin—thyroid cancer	0.0173	0.0375	CbGbCtD
Loperamide—Altered state of consciousness—Vandetanib—thyroid cancer	0.0118	0.0745	CcSEcCtD
Loperamide—POMC—neck—thyroid cancer	0.0114	0.168	CbGeAlD
Loperamide—Ileus—Vandetanib—thyroid cancer	0.00769	0.0486	CcSEcCtD
Loperamide—POMC—thyroid gland—thyroid cancer	0.00541	0.0799	CbGeAlD
Loperamide—Depressed level of consciousness—Vandetanib—thyroid cancer	0.00525	0.0332	CcSEcCtD
Loperamide—POMC—head—thyroid cancer	0.0048	0.0709	CbGeAlD
Loperamide—CACNA1A—head—thyroid cancer	0.00458	0.0677	CbGeAlD
Loperamide—Dermatitis bullous—Vandetanib—thyroid cancer	0.00413	0.0261	CcSEcCtD
Loperamide—Bullous eruption—Epirubicin—thyroid cancer	0.00343	0.0217	CcSEcCtD
Loperamide—Bullous eruption—Doxorubicin—thyroid cancer	0.00317	0.0201	CcSEcCtD
Loperamide—CALM2—neck—thyroid cancer	0.0031	0.0458	CbGeAlD
Loperamide—CALM1—neck—thyroid cancer	0.00309	0.0456	CbGeAlD
Loperamide—CALM3—saliva-secreting gland—thyroid cancer	0.00308	0.0455	CbGeAlD
Loperamide—Stevens-Johnson syndrome—Vandetanib—thyroid cancer	0.00302	0.0191	CcSEcCtD
Loperamide—Urinary tract disorder—Vandetanib—thyroid cancer	0.0027	0.0171	CcSEcCtD
Loperamide—Urethral disorder—Vandetanib—thyroid cancer	0.00268	0.0169	CcSEcCtD
Loperamide—OPRD1—head—thyroid cancer	0.00265	0.0391	CbGeAlD
Loperamide—Erythema multiforme—Vandetanib—thyroid cancer	0.00258	0.0163	CcSEcCtD
Loperamide—OPRK1—head—thyroid cancer	0.00254	0.0375	CbGeAlD
Loperamide—Abdominal pain upper—Sorafenib—thyroid cancer	0.00243	0.0154	CcSEcCtD
Loperamide—CALM2—saliva-secreting gland—thyroid cancer	0.00242	0.0358	CbGeAlD
Loperamide—CALM1—saliva-secreting gland—thyroid cancer	0.00241	0.0356	CbGeAlD
Loperamide—Toxic epidermal necrolysis—Sorafenib—thyroid cancer	0.0024	0.0152	CcSEcCtD
Loperamide—CALM3—trachea—thyroid cancer	0.00238	0.0351	CbGeAlD
Loperamide—Loss of consciousness—Vandetanib—thyroid cancer	0.00209	0.0132	CcSEcCtD
Loperamide—Stevens-Johnson syndrome—Sorafenib—thyroid cancer	0.00204	0.0129	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00201	0.0127	CcSEcCtD
Loperamide—Dry mouth—Vandetanib—thyroid cancer	0.00198	0.0125	CcSEcCtD
Loperamide—Ileus—Epirubicin—thyroid cancer	0.00192	0.0121	CcSEcCtD
Loperamide—Nervous system disorder—Vandetanib—thyroid cancer	0.0019	0.012	CcSEcCtD
Loperamide—Skin disorder—Vandetanib—thyroid cancer	0.00189	0.0119	CcSEcCtD
Loperamide—CALM3—thyroid gland—thyroid cancer	0.00188	0.0278	CbGeAlD
Loperamide—CALM2—trachea—thyroid cancer	0.00187	0.0276	CbGeAlD
Loperamide—CALM1—trachea—thyroid cancer	0.00186	0.0275	CbGeAlD
Loperamide—Urinary tract disorder—Sorafenib—thyroid cancer	0.00182	0.0115	CcSEcCtD
Loperamide—Urethral disorder—Sorafenib—thyroid cancer	0.00181	0.0114	CcSEcCtD
Loperamide—OPRM1—head—thyroid cancer	0.00181	0.0267	CbGeAlD
Loperamide—Ileus—Doxorubicin—thyroid cancer	0.00177	0.0112	CcSEcCtD
Loperamide—Erythema multiforme—Sorafenib—thyroid cancer	0.00174	0.011	CcSEcCtD
Loperamide—Dyspepsia—Vandetanib—thyroid cancer	0.00171	0.0108	CcSEcCtD
Loperamide—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00168	0.0106	CcSEcCtD
Loperamide—Fatigue—Vandetanib—thyroid cancer	0.00167	0.0106	CcSEcCtD
Loperamide—Immune system disorder—Sorafenib—thyroid cancer	0.00166	0.0105	CcSEcCtD
Loperamide—Constipation—Vandetanib—thyroid cancer	0.00166	0.0105	CcSEcCtD
Loperamide—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00159	0.01	CcSEcCtD
Loperamide—Abdominal pain—Vandetanib—thyroid cancer	0.00153	0.0097	CcSEcCtD
Loperamide—CALM2—thyroid gland—thyroid cancer	0.00148	0.0218	CbGeAlD
Loperamide—CALM1—thyroid gland—thyroid cancer	0.00147	0.0217	CbGeAlD
Loperamide—Angioedema—Sorafenib—thyroid cancer	0.00147	0.00927	CcSEcCtD
Loperamide—Loss of consciousness—Sorafenib—thyroid cancer	0.00141	0.00892	CcSEcCtD
Loperamide—Asthenia—Vandetanib—thyroid cancer	0.00139	0.00881	CcSEcCtD
Loperamide—Pruritus—Vandetanib—thyroid cancer	0.00137	0.00869	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00136	0.00858	CcSEcCtD
Loperamide—Dry mouth—Sorafenib—thyroid cancer	0.00134	0.00845	CcSEcCtD
Loperamide—Diarrhoea—Vandetanib—thyroid cancer	0.00133	0.0084	CcSEcCtD
Loperamide—CALM2—head—thyroid cancer	0.00131	0.0194	CbGeAlD
Loperamide—Anaphylactic shock—Sorafenib—thyroid cancer	0.00131	0.00828	CcSEcCtD
Loperamide—CALM1—head—thyroid cancer	0.0013	0.0193	CbGeAlD
Loperamide—Nervous system disorder—Sorafenib—thyroid cancer	0.00128	0.00812	CcSEcCtD
Loperamide—Dizziness—Vandetanib—thyroid cancer	0.00128	0.00812	CcSEcCtD
Loperamide—Skin disorder—Sorafenib—thyroid cancer	0.00127	0.00804	CcSEcCtD
Loperamide—Vomiting—Vandetanib—thyroid cancer	0.00123	0.00781	CcSEcCtD
Loperamide—Rash—Vandetanib—thyroid cancer	0.00122	0.00774	CcSEcCtD
Loperamide—Dermatitis—Vandetanib—thyroid cancer	0.00122	0.00773	CcSEcCtD
Loperamide—Headache—Vandetanib—thyroid cancer	0.00122	0.00769	CcSEcCtD
Loperamide—CALM3—lymph node—thyroid cancer	0.00117	0.0173	CbGeAlD
Loperamide—Nausea—Vandetanib—thyroid cancer	0.00115	0.00729	CcSEcCtD
Loperamide—Dyspepsia—Sorafenib—thyroid cancer	0.00115	0.00729	CcSEcCtD
Loperamide—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00113	0.00715	CcSEcCtD
Loperamide—Fatigue—Sorafenib—thyroid cancer	0.00113	0.00714	CcSEcCtD
Loperamide—Constipation—Sorafenib—thyroid cancer	0.00112	0.00708	CcSEcCtD
Loperamide—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00107	0.00677	CcSEcCtD
Loperamide—Urticaria—Sorafenib—thyroid cancer	0.00104	0.00658	CcSEcCtD
Loperamide—Abdominal pain—Sorafenib—thyroid cancer	0.00103	0.00655	CcSEcCtD
Loperamide—Dermatitis bullous—Epirubicin—thyroid cancer	0.00103	0.00652	CcSEcCtD
Loperamide—Anaphylactoid reaction—Epirubicin—thyroid cancer	0.00102	0.00643	CcSEcCtD
Loperamide—CYP2B6—head—thyroid cancer	0.000975	0.0144	CbGeAlD
Loperamide—Hypersensitivity—Sorafenib—thyroid cancer	0.000965	0.0061	CcSEcCtD
Loperamide—Dermatitis bullous—Doxorubicin—thyroid cancer	0.000953	0.00603	CcSEcCtD
Loperamide—Anaphylactoid reaction—Doxorubicin—thyroid cancer	0.000941	0.00595	CcSEcCtD
Loperamide—Asthenia—Sorafenib—thyroid cancer	0.000939	0.00594	CcSEcCtD
Loperamide—Pruritus—Sorafenib—thyroid cancer	0.000926	0.00586	CcSEcCtD
Loperamide—CALM2—lymph node—thyroid cancer	0.000918	0.0136	CbGeAlD
Loperamide—CALM1—lymph node—thyroid cancer	0.000914	0.0135	CbGeAlD
Loperamide—Abdominal pain upper—Epirubicin—thyroid cancer	0.000899	0.00569	CcSEcCtD
Loperamide—Diarrhoea—Sorafenib—thyroid cancer	0.000896	0.00567	CcSEcCtD
Loperamide—Toxic epidermal necrolysis—Epirubicin—thyroid cancer	0.000887	0.00561	CcSEcCtD
Loperamide—Dizziness—Sorafenib—thyroid cancer	0.000866	0.00548	CcSEcCtD
Loperamide—Abdominal distension—Epirubicin—thyroid cancer	0.000857	0.00542	CcSEcCtD
Loperamide—Vomiting—Sorafenib—thyroid cancer	0.000832	0.00527	CcSEcCtD
Loperamide—Abdominal pain upper—Doxorubicin—thyroid cancer	0.000832	0.00526	CcSEcCtD
Loperamide—Rash—Sorafenib—thyroid cancer	0.000826	0.00522	CcSEcCtD
Loperamide—Dermatitis—Sorafenib—thyroid cancer	0.000825	0.00522	CcSEcCtD
Loperamide—Toxic epidermal necrolysis—Doxorubicin—thyroid cancer	0.00082	0.00519	CcSEcCtD
Loperamide—Headache—Sorafenib—thyroid cancer	0.00082	0.00519	CcSEcCtD
Loperamide—Abdominal distension—Doxorubicin—thyroid cancer	0.000793	0.00501	CcSEcCtD
Loperamide—Nausea—Sorafenib—thyroid cancer	0.000778	0.00492	CcSEcCtD
Loperamide—Drowsiness—Epirubicin—thyroid cancer	0.000759	0.0048	CcSEcCtD
Loperamide—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	0.000752	0.00476	CcSEcCtD
Loperamide—ABCB1—trachea—thyroid cancer	0.000742	0.011	CbGeAlD
Loperamide—CYP2D6—head—thyroid cancer	0.000724	0.0107	CbGeAlD
Loperamide—Drowsiness—Doxorubicin—thyroid cancer	0.000702	0.00444	CcSEcCtD
Loperamide—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	0.000696	0.0044	CcSEcCtD
Loperamide—Urinary tract disorder—Epirubicin—thyroid cancer	0.000673	0.00425	CcSEcCtD
Loperamide—Urethral disorder—Epirubicin—thyroid cancer	0.000668	0.00422	CcSEcCtD
Loperamide—Erythema multiforme—Epirubicin—thyroid cancer	0.000644	0.00407	CcSEcCtD
Loperamide—Urinary tract disorder—Doxorubicin—thyroid cancer	0.000622	0.00394	CcSEcCtD
Loperamide—Urethral disorder—Doxorubicin—thyroid cancer	0.000618	0.00391	CcSEcCtD
Loperamide—Immune system disorder—Epirubicin—thyroid cancer	0.000615	0.00389	CcSEcCtD
Loperamide—Erythema multiforme—Doxorubicin—thyroid cancer	0.000596	0.00377	CcSEcCtD
Loperamide—ABCB1—thyroid gland—thyroid cancer	0.000587	0.00867	CbGeAlD
Loperamide—Flatulence—Epirubicin—thyroid cancer	0.000584	0.0037	CcSEcCtD
Loperamide—Immune system disorder—Doxorubicin—thyroid cancer	0.000569	0.0036	CcSEcCtD
Loperamide—Flatulence—Doxorubicin—thyroid cancer	0.000541	0.00342	CcSEcCtD
Loperamide—Loss of consciousness—Epirubicin—thyroid cancer	0.000521	0.0033	CcSEcCtD
Loperamide—ABCB1—head—thyroid cancer	0.000521	0.00769	CbGeAlD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000501	0.00317	CcSEcCtD
Loperamide—Discomfort—Epirubicin—thyroid cancer	0.000499	0.00315	CcSEcCtD
Loperamide—Dry mouth—Epirubicin—thyroid cancer	0.000494	0.00312	CcSEcCtD
Loperamide—Anaphylactic shock—Epirubicin—thyroid cancer	0.000484	0.00306	CcSEcCtD
Loperamide—Loss of consciousness—Doxorubicin—thyroid cancer	0.000482	0.00305	CcSEcCtD
Loperamide—Nervous system disorder—Epirubicin—thyroid cancer	0.000475	0.003	CcSEcCtD
Loperamide—Skin disorder—Epirubicin—thyroid cancer	0.00047	0.00297	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000464	0.00293	CcSEcCtD
Loperamide—Discomfort—Doxorubicin—thyroid cancer	0.000461	0.00292	CcSEcCtD
Loperamide—Dry mouth—Doxorubicin—thyroid cancer	0.000457	0.00289	CcSEcCtD
Loperamide—Anaphylactic shock—Doxorubicin—thyroid cancer	0.000448	0.00283	CcSEcCtD
Loperamide—Nervous system disorder—Doxorubicin—thyroid cancer	0.000439	0.00278	CcSEcCtD
Loperamide—Skin disorder—Doxorubicin—thyroid cancer	0.000435	0.00275	CcSEcCtD
Loperamide—Somnolence—Epirubicin—thyroid cancer	0.00043	0.00272	CcSEcCtD
Loperamide—Dyspepsia—Epirubicin—thyroid cancer	0.000426	0.00269	CcSEcCtD
Loperamide—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000418	0.00264	CcSEcCtD
Loperamide—Fatigue—Epirubicin—thyroid cancer	0.000417	0.00264	CcSEcCtD
Loperamide—Constipation—Epirubicin—thyroid cancer	0.000414	0.00262	CcSEcCtD
Loperamide—Somnolence—Doxorubicin—thyroid cancer	0.000398	0.00252	CcSEcCtD
Loperamide—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000396	0.0025	CcSEcCtD
Loperamide—Dyspepsia—Doxorubicin—thyroid cancer	0.000394	0.00249	CcSEcCtD
Loperamide—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000387	0.00244	CcSEcCtD
Loperamide—Fatigue—Doxorubicin—thyroid cancer	0.000386	0.00244	CcSEcCtD
Loperamide—Urticaria—Epirubicin—thyroid cancer	0.000384	0.00243	CcSEcCtD
Loperamide—Constipation—Doxorubicin—thyroid cancer	0.000383	0.00242	CcSEcCtD
Loperamide—Abdominal pain—Epirubicin—thyroid cancer	0.000382	0.00242	CcSEcCtD
Loperamide—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000366	0.00232	CcSEcCtD
Loperamide—ABCB1—lymph node—thyroid cancer	0.000365	0.00539	CbGeAlD
Loperamide—Hypersensitivity—Epirubicin—thyroid cancer	0.000356	0.00225	CcSEcCtD
Loperamide—Urticaria—Doxorubicin—thyroid cancer	0.000356	0.00225	CcSEcCtD
Loperamide—Abdominal pain—Doxorubicin—thyroid cancer	0.000354	0.00224	CcSEcCtD
Loperamide—Asthenia—Epirubicin—thyroid cancer	0.000347	0.0022	CcSEcCtD
Loperamide—Pruritus—Epirubicin—thyroid cancer	0.000342	0.00217	CcSEcCtD
Loperamide—Diarrhoea—Epirubicin—thyroid cancer	0.000331	0.00209	CcSEcCtD
Loperamide—Hypersensitivity—Doxorubicin—thyroid cancer	0.00033	0.00209	CcSEcCtD
Loperamide—Asthenia—Doxorubicin—thyroid cancer	0.000321	0.00203	CcSEcCtD
Loperamide—Dizziness—Epirubicin—thyroid cancer	0.00032	0.00202	CcSEcCtD
Loperamide—Pruritus—Doxorubicin—thyroid cancer	0.000317	0.002	CcSEcCtD
Loperamide—Vomiting—Epirubicin—thyroid cancer	0.000308	0.00195	CcSEcCtD
Loperamide—Diarrhoea—Doxorubicin—thyroid cancer	0.000306	0.00194	CcSEcCtD
Loperamide—Rash—Epirubicin—thyroid cancer	0.000305	0.00193	CcSEcCtD
Loperamide—Dermatitis—Epirubicin—thyroid cancer	0.000305	0.00193	CcSEcCtD
Loperamide—Headache—Epirubicin—thyroid cancer	0.000303	0.00192	CcSEcCtD
Loperamide—Dizziness—Doxorubicin—thyroid cancer	0.000296	0.00187	CcSEcCtD
Loperamide—Nausea—Epirubicin—thyroid cancer	0.000287	0.00182	CcSEcCtD
Loperamide—Vomiting—Doxorubicin—thyroid cancer	0.000285	0.0018	CcSEcCtD
Loperamide—Rash—Doxorubicin—thyroid cancer	0.000282	0.00179	CcSEcCtD
Loperamide—Dermatitis—Doxorubicin—thyroid cancer	0.000282	0.00178	CcSEcCtD
Loperamide—Headache—Doxorubicin—thyroid cancer	0.00028	0.00177	CcSEcCtD
Loperamide—Nausea—Doxorubicin—thyroid cancer	0.000266	0.00168	CcSEcCtD
Loperamide—CALM3—Signaling by NGF—HRAS—thyroid cancer	3.8e-05	0.000121	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—PTCH1—thyroid cancer	3.77e-05	0.00012	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—PTCH1—thyroid cancer	3.77e-05	0.00012	CbGpPWpGaD
Loperamide—CALM1—Neuronal System—HRAS—thyroid cancer	3.75e-05	0.00012	CbGpPWpGaD
Loperamide—CALM2—Neuronal System—HRAS—thyroid cancer	3.75e-05	0.00012	CbGpPWpGaD
Loperamide—CALM3—Signaling by WNT in cancer—AKT1—thyroid cancer	3.74e-05	0.000119	CbGpPWpGaD
Loperamide—CALM1—Immune System—NRG1—thyroid cancer	3.73e-05	0.000119	CbGpPWpGaD
Loperamide—CALM2—Immune System—NRG1—thyroid cancer	3.73e-05	0.000119	CbGpPWpGaD
Loperamide—CALM1—Signaling by NGF—HRAS—thyroid cancer	3.67e-05	0.000117	CbGpPWpGaD
Loperamide—CALM2—Signaling by NGF—HRAS—thyroid cancer	3.67e-05	0.000117	CbGpPWpGaD
Loperamide—CALM2—Signaling by WNT in cancer—AKT1—thyroid cancer	3.62e-05	0.000116	CbGpPWpGaD
Loperamide—CALM1—Signaling by WNT in cancer—AKT1—thyroid cancer	3.62e-05	0.000116	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—TERT—thyroid cancer	3.62e-05	0.000115	CbGpPWpGaD
Loperamide—OPRK1—Signaling by GPCR—NRAS—thyroid cancer	3.61e-05	0.000115	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—SLC5A5—thyroid cancer	3.57e-05	0.000114	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—SST—thyroid cancer	3.57e-05	0.000114	CbGpPWpGaD
Loperamide—CALM3—Disease—NRG1—thyroid cancer	3.56e-05	0.000114	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—RXRA—thyroid cancer	3.54e-05	0.000113	CbGpPWpGaD
Loperamide—OPRD1—Signaling by GPCR—KRAS—thyroid cancer	3.54e-05	0.000113	CbGpPWpGaD
Loperamide—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	3.51e-05	0.000112	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—HIF1A—thyroid cancer	3.46e-05	0.00011	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—SST—thyroid cancer	3.45e-05	0.00011	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—SST—thyroid cancer	3.45e-05	0.00011	CbGpPWpGaD
Loperamide—CALM3—Metabolism—RXRA—thyroid cancer	3.45e-05	0.00011	CbGpPWpGaD
Loperamide—CALM2—Disease—NRG1—thyroid cancer	3.44e-05	0.00011	CbGpPWpGaD
Loperamide—CALM1—Disease—NRG1—thyroid cancer	3.44e-05	0.00011	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CALCA—thyroid cancer	3.43e-05	0.00011	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—BRAF—thyroid cancer	3.39e-05	0.000108	CbGpPWpGaD
Loperamide—CALM3—Signaling by NGF—AKT1—thyroid cancer	3.35e-05	0.000107	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	3.35e-05	0.000107	CbGpPWpGaD
Loperamide—CALM1—Metabolism—RXRA—thyroid cancer	3.34e-05	0.000106	CbGpPWpGaD
Loperamide—CALM2—Metabolism—RXRA—thyroid cancer	3.34e-05	0.000106	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CALCA—thyroid cancer	3.32e-05	0.000106	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CALCA—thyroid cancer	3.32e-05	0.000106	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—PTEN—thyroid cancer	3.32e-05	0.000106	CbGpPWpGaD
Loperamide—CALM3—Hemostasis—NRAS—thyroid cancer	3.29e-05	0.000105	CbGpPWpGaD
Loperamide—CALM2—Signaling by NGF—AKT1—thyroid cancer	3.24e-05	0.000103	CbGpPWpGaD
Loperamide—CALM1—Signaling by NGF—AKT1—thyroid cancer	3.24e-05	0.000103	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—PTEN—thyroid cancer	3.21e-05	0.000102	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—PTEN—thyroid cancer	3.21e-05	0.000102	CbGpPWpGaD
Loperamide—CALM3—Disease—TERT—thyroid cancer	3.2e-05	0.000102	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—PTEN—thyroid cancer	3.19e-05	0.000102	CbGpPWpGaD
Loperamide—CALM1—Hemostasis—NRAS—thyroid cancer	3.18e-05	0.000101	CbGpPWpGaD
Loperamide—CALM2—Hemostasis—NRAS—thyroid cancer	3.18e-05	0.000101	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—SLC5A5—thyroid cancer	3.11e-05	9.93e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CDK1—thyroid cancer	3.11e-05	9.91e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling by GPCR—KRAS—thyroid cancer	3.1e-05	9.9e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—TERT—thyroid cancer	3.09e-05	9.87e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—TERT—thyroid cancer	3.09e-05	9.87e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by Wnt—AKT1—thyroid cancer	3.09e-05	9.85e-05	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—PTEN—thyroid cancer	3.08e-05	9.83e-05	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—PTEN—thyroid cancer	3.08e-05	9.83e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—HIF1A—thyroid cancer	3.06e-05	9.76e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—NRAS—thyroid cancer	3.05e-05	9.73e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling by GPCR—HRAS—thyroid cancer	3.01e-05	9.6e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CDK1—thyroid cancer	3.01e-05	9.59e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CDK1—thyroid cancer	3.01e-05	9.59e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—RXRA—thyroid cancer	3e-05	9.57e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by Wnt—AKT1—thyroid cancer	2.99e-05	9.53e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by Wnt—AKT1—thyroid cancer	2.99e-05	9.53e-05	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—NRAS—thyroid cancer	2.96e-05	9.44e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—HIF1A—thyroid cancer	2.96e-05	9.44e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—HIF1A—thyroid cancer	2.96e-05	9.44e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—SLC5A5—thyroid cancer	2.93e-05	9.35e-05	CbGpPWpGaD
Loperamide—OPRD1—GPCR downstream signaling—AKT1—thyroid cancer	2.93e-05	9.34e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	2.92e-05	9.31e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—BRAF—thyroid cancer	2.86e-05	9.14e-05	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—NRAS—thyroid cancer	2.86e-05	9.14e-05	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—NRAS—thyroid cancer	2.86e-05	9.14e-05	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—NRAS—thyroid cancer	2.84e-05	9.07e-05	CbGpPWpGaD
Loperamide—CALM3—Hemostasis—KRAS—thyroid cancer	2.83e-05	9.03e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—CCND1—thyroid cancer	2.82e-05	9e-05	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—NRAS—thyroid cancer	2.75e-05	8.77e-05	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—NRAS—thyroid cancer	2.75e-05	8.77e-05	CbGpPWpGaD
Loperamide—CALM2—Hemostasis—KRAS—thyroid cancer	2.74e-05	8.73e-05	CbGpPWpGaD
Loperamide—CALM1—Hemostasis—KRAS—thyroid cancer	2.74e-05	8.73e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—PTEN—thyroid cancer	2.72e-05	8.69e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling by GPCR—AKT1—thyroid cancer	2.66e-05	8.48e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling by GPCR—HRAS—thyroid cancer	2.64e-05	8.42e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—KRAS—thyroid cancer	2.62e-05	8.37e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—RXRA—thyroid cancer	2.61e-05	8.34e-05	CbGpPWpGaD
Loperamide—OPRK1—GPCR downstream signaling—AKT1—thyroid cancer	2.56e-05	8.19e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—TPR—thyroid cancer	2.56e-05	8.17e-05	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—KRAS—thyroid cancer	2.55e-05	8.13e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—BRAF—thyroid cancer	2.53e-05	8.08e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	2.52e-05	8.04e-05	CbGpPWpGaD
Loperamide—CALM3—Hemostasis—TP53—thyroid cancer	2.51e-05	8.02e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—NRG1—thyroid cancer	2.49e-05	7.96e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—CCND1—thyroid cancer	2.47e-05	7.89e-05	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—KRAS—thyroid cancer	2.46e-05	7.86e-05	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—KRAS—thyroid cancer	2.46e-05	7.86e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—RXRA—thyroid cancer	2.46e-05	7.86e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—BRAF—thyroid cancer	2.45e-05	7.82e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—BRAF—thyroid cancer	2.45e-05	7.82e-05	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—KRAS—thyroid cancer	2.45e-05	7.81e-05	CbGpPWpGaD
Loperamide—CALM2—Hemostasis—TP53—thyroid cancer	2.43e-05	7.76e-05	CbGpPWpGaD
Loperamide—CALM1—Hemostasis—TP53—thyroid cancer	2.43e-05	7.76e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—NRAS—thyroid cancer	2.43e-05	7.75e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—NRG1—thyroid cancer	2.41e-05	7.7e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—NRG1—thyroid cancer	2.41e-05	7.7e-05	CbGpPWpGaD
Loperamide—CALM3—Hemostasis—HRAS—thyroid cancer	2.4e-05	7.67e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—PTEN—thyroid cancer	2.39e-05	7.62e-05	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—KRAS—thyroid cancer	2.37e-05	7.55e-05	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—KRAS—thyroid cancer	2.37e-05	7.55e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling by GPCR—AKT1—thyroid cancer	2.33e-05	7.43e-05	CbGpPWpGaD
Loperamide—CALM1—Hemostasis—HRAS—thyroid cancer	2.33e-05	7.42e-05	CbGpPWpGaD
Loperamide—CALM2—Hemostasis—HRAS—thyroid cancer	2.33e-05	7.42e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—TERT—thyroid cancer	2.24e-05	7.15e-05	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—PPARG—thyroid cancer	2.24e-05	7.14e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—HRAS—thyroid cancer	2.23e-05	7.11e-05	CbGpPWpGaD
Loperamide—CALM3—Metabolism—PPARG—thyroid cancer	2.18e-05	6.95e-05	CbGpPWpGaD
Loperamide—OPRM1—GPCR downstream signaling—AKT1—thyroid cancer	2.17e-05	6.92e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—TERT—thyroid cancer	2.17e-05	6.91e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—TERT—thyroid cancer	2.17e-05	6.91e-05	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—HRAS—thyroid cancer	2.16e-05	6.91e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—HIF1A—thyroid cancer	2.14e-05	6.83e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—NRAS—thyroid cancer	2.13e-05	6.8e-05	CbGpPWpGaD
Loperamide—CALM3—Hemostasis—AKT1—thyroid cancer	2.12e-05	6.78e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—PPARG—thyroid cancer	2.11e-05	6.72e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—PPARG—thyroid cancer	2.11e-05	6.72e-05	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—HRAS—thyroid cancer	2.09e-05	6.68e-05	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—HRAS—thyroid cancer	2.09e-05	6.68e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—KRAS—thyroid cancer	2.09e-05	6.67e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—CCND1—thyroid cancer	2.09e-05	6.67e-05	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—HRAS—thyroid cancer	2.08e-05	6.63e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—HIF1A—thyroid cancer	2.07e-05	6.61e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—HIF1A—thyroid cancer	2.07e-05	6.61e-05	CbGpPWpGaD
Loperamide—CALM1—Hemostasis—AKT1—thyroid cancer	2.05e-05	6.55e-05	CbGpPWpGaD
Loperamide—CALM2—Hemostasis—AKT1—thyroid cancer	2.05e-05	6.55e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—PTGS2—thyroid cancer	2.05e-05	6.53e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—PTEN—thyroid cancer	2.02e-05	6.44e-05	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—HRAS—thyroid cancer	2.01e-05	6.42e-05	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—HRAS—thyroid cancer	2.01e-05	6.42e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—PTGS2—thyroid cancer	1.98e-05	6.31e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—PTGS2—thyroid cancer	1.98e-05	6.31e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—AKT1—thyroid cancer	1.97e-05	6.28e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—PTEN—thyroid cancer	1.93e-05	6.17e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—SLC5A5—thyroid cancer	1.92e-05	6.12e-05	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—AKT1—thyroid cancer	1.91e-05	6.1e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—PPARG—thyroid cancer	1.89e-05	6.04e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—NRAS—thyroid cancer	1.89e-05	6.02e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—PTEN—thyroid cancer	1.87e-05	5.96e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—PTEN—thyroid cancer	1.87e-05	5.96e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—TP53—thyroid cancer	1.86e-05	5.93e-05	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—AKT1—thyroid cancer	1.85e-05	5.9e-05	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—AKT1—thyroid cancer	1.85e-05	5.9e-05	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—AKT1—thyroid cancer	1.84e-05	5.86e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—KRAS—thyroid cancer	1.83e-05	5.85e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—NRAS—thyroid cancer	1.82e-05	5.82e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—NRAS—thyroid cancer	1.82e-05	5.82e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—NRAS—thyroid cancer	1.8e-05	5.75e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—PTEN—thyroid cancer	1.78e-05	5.69e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—HRAS—thyroid cancer	1.78e-05	5.67e-05	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—AKT1—thyroid cancer	1.78e-05	5.67e-05	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—AKT1—thyroid cancer	1.78e-05	5.67e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—BRAF—thyroid cancer	1.77e-05	5.66e-05	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—PTGS2—thyroid cancer	1.76e-05	5.62e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—PTEN—thyroid cancer	1.73e-05	5.51e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—PTEN—thyroid cancer	1.73e-05	5.51e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—NRAS—thyroid cancer	1.72e-05	5.5e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—BRAF—thyroid cancer	1.72e-05	5.47e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—BRAF—thyroid cancer	1.72e-05	5.47e-05	CbGpPWpGaD
Loperamide—CALM3—Metabolism—PTGS2—thyroid cancer	1.71e-05	5.47e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—NRAS—thyroid cancer	1.67e-05	5.32e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—NRAS—thyroid cancer	1.67e-05	5.32e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—PTGS2—thyroid cancer	1.66e-05	5.29e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—PTGS2—thyroid cancer	1.66e-05	5.29e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—PPARG—thyroid cancer	1.65e-05	5.27e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—TP53—thyroid cancer	1.63e-05	5.2e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—KRAS—thyroid cancer	1.62e-05	5.18e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—RXRA—thyroid cancer	1.61e-05	5.14e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—NRAS—thyroid cancer	1.59e-05	5.08e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—KRAS—thyroid cancer	1.57e-05	5.01e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—KRAS—thyroid cancer	1.57e-05	5.01e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—AKT1—thyroid cancer	1.57e-05	5.01e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—HRAS—thyroid cancer	1.56e-05	4.97e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—PPARG—thyroid cancer	1.56e-05	4.96e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—KRAS—thyroid cancer	1.55e-05	4.94e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—NRAS—thyroid cancer	1.54e-05	4.91e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—NRAS—thyroid cancer	1.54e-05	4.91e-05	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—PTEN—thyroid cancer	1.53e-05	4.9e-05	CbGpPWpGaD
Loperamide—CALM3—Metabolism—PTEN—thyroid cancer	1.49e-05	4.77e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—PTGS2—thyroid cancer	1.49e-05	4.76e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—KRAS—thyroid cancer	1.48e-05	4.73e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—PTEN—thyroid cancer	1.45e-05	4.61e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—PTEN—thyroid cancer	1.45e-05	4.61e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—KRAS—thyroid cancer	1.44e-05	4.58e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—KRAS—thyroid cancer	1.44e-05	4.58e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—HRAS—thyroid cancer	1.38e-05	4.4e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—TP53—thyroid cancer	1.38e-05	4.39e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—AKT1—thyroid cancer	1.38e-05	4.39e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—KRAS—thyroid cancer	1.37e-05	4.37e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—HRAS—thyroid cancer	1.34e-05	4.26e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—HRAS—thyroid cancer	1.34e-05	4.26e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—KRAS—thyroid cancer	1.32e-05	4.23e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—KRAS—thyroid cancer	1.32e-05	4.23e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—HRAS—thyroid cancer	1.32e-05	4.2e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—PTEN—thyroid cancer	1.3e-05	4.15e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—PTGS2—thyroid cancer	1.3e-05	4.14e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CCND1—thyroid cancer	1.29e-05	4.13e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—HRAS—thyroid cancer	1.26e-05	4.02e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CCND1—thyroid cancer	1.25e-05	4e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CCND1—thyroid cancer	1.25e-05	4e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—PTEN—thyroid cancer	1.25e-05	3.99e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—PTGS2—thyroid cancer	1.22e-05	3.9e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—HRAS—thyroid cancer	1.22e-05	3.89e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—HRAS—thyroid cancer	1.22e-05	3.89e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—AKT1—thyroid cancer	1.22e-05	3.89e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—PTEN—thyroid cancer	1.21e-05	3.86e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—PTEN—thyroid cancer	1.21e-05	3.86e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—AKT1—thyroid cancer	1.18e-05	3.76e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—AKT1—thyroid cancer	1.18e-05	3.76e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—HRAS—thyroid cancer	1.16e-05	3.72e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—AKT1—thyroid cancer	1.16e-05	3.71e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—PTEN—thyroid cancer	1.13e-05	3.61e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—HRAS—thyroid cancer	1.13e-05	3.59e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—HRAS—thyroid cancer	1.13e-05	3.59e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—NRAS—thyroid cancer	1.11e-05	3.56e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—AKT1—thyroid cancer	1.11e-05	3.55e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—NRAS—thyroid cancer	1.08e-05	3.44e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—NRAS—thyroid cancer	1.08e-05	3.44e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—AKT1—thyroid cancer	1.08e-05	3.44e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—AKT1—thyroid cancer	1.08e-05	3.44e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—PTEN—thyroid cancer	1.07e-05	3.4e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—AKT1—thyroid cancer	1.03e-05	3.28e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PPARG—thyroid cancer	1.02e-05	3.24e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—AKT1—thyroid cancer	9.94e-06	3.17e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—AKT1—thyroid cancer	9.94e-06	3.17e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—KRAS—thyroid cancer	9.59e-06	3.06e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—KRAS—thyroid cancer	9.28e-06	2.96e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—KRAS—thyroid cancer	9.28e-06	2.96e-05	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—AKT1—thyroid cancer	8.85e-06	2.82e-05	CbGpPWpGaD
Loperamide—CALM3—Metabolism—AKT1—thyroid cancer	8.61e-06	2.75e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—TP53—thyroid cancer	8.52e-06	2.72e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—AKT1—thyroid cancer	8.33e-06	2.66e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—AKT1—thyroid cancer	8.33e-06	2.66e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—TP53—thyroid cancer	8.25e-06	2.63e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—TP53—thyroid cancer	8.25e-06	2.63e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—HRAS—thyroid cancer	8.15e-06	2.6e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PTGS2—thyroid cancer	8e-06	2.55e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—HRAS—thyroid cancer	7.89e-06	2.52e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—HRAS—thyroid cancer	7.89e-06	2.52e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—AKT1—thyroid cancer	7.49e-06	2.39e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—AKT1—thyroid cancer	7.2e-06	2.3e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PTEN—thyroid cancer	6.97e-06	2.23e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—AKT1—thyroid cancer	6.96e-06	2.22e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—AKT1—thyroid cancer	6.96e-06	2.22e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—AKT1—thyroid cancer	6.52e-06	2.08e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—AKT1—thyroid cancer	6.15e-06	1.96e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—AKT1—thyroid cancer	4.02e-06	1.28e-05	CbGpPWpGaD
